SBIR-STTR Award

Development of an Interference Electroporation Device to Improve Targeted Cell Pe
Award last edited on: 4/20/21

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$162,701
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Brian McCluskey

Company Information

OncoSec Medical Inc (AKA: Netventory Solutions, Inc.)

24 North Main Street
Pennington, NJ 08534
   (855) 662-6732
   investors@oncosec.com
   www.oncosec.com
Location: Single
Congr. District: 12
County: Mercer

Phase I

Contract Number: 1R43CA183242-01A1
Start Date: 9/18/14    Completed: 3/17/15
Phase I year
2014
Phase I Amount
$162,701
Here we seek to develop a more effective and targeted electroporation device for the clinical treatment of cancerous solid tumors. The application of using electroporation to transfect therapeutic agents into a tumor cells in the clinician setting is an exciting approach to a targeted treatment of cancer. The challenge for thiswork is to further develop a clinical electroporation device that will use the phenomenon of wave interference to produce a targeted electroporation waveform to increase the effectiveness of transfection.

Thesaurus Terms:
Address;Adverse Effects;Algorithms;Alternative Treatment;Animals;Antineoplastic Agents;Base;Biological Products;Cancer Cell;Cancer Patient;Cancer Therapy;Cancerous;Cells;Cessation Of Life;Chemotherapy;Clinical;Clinical Research;Clinical Treatment;Clinical Trials;Computer Simulation;Computer Software;Design;Development;Devices;Disease;Disseminated Malignant Neoplasm;Effectiveness;Electric Field;Electroporation;Ensure;Equation;Frequencies (Time Pattern);Future;Genes;Immunotherapy;Improved;In Vivo;Instrument;Instrumentation;Mathematical Analysis;Medical;Melanoma;Methods;Model Development;Modeling;Neoplastic Cell;Novel;Novel Strategies;Operative Surgical Procedures;Outcome;Phase;Plasmid Dna;Product Development;Programs;Prototype;Public Health Relevance;Quality Of Life;Reporting;Research;Research Study;Signal Transduction;Simulation;Skin Cancer;Solid Neoplasm;Solutions;Staging;Techniques;Technology;Testing;Therapeutic Agents;Time;Toxic Effect;Transfection;Treatment Planning;Tumor;Uptake;Work;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----